Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.41 |
| ▸ | FLT1 | P17948 | 4/20 | 0.37 |
| ▸ | FLT4 | P35916 | 4/20 | 0.37 |
| ▸ | KDR | P35968 | 4/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.34 |
| ▸ | ACLY | P53396 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17647009 | 1.00 | EGFR (0.41) | EGFRFLT1FLT4KDRSCN9A | |
| SCHEMBL17648558 | 0.92 | EGFR (0.36) | EGFRFLT1FLT4KDRSCN9A | |
| SCHEMBL29916753 | 0.92 | EGFR (0.36) | EGFRFLT1FLT4KDRSCN9A | |
| SCHEMBL17647181 | 0.91 | FLT1 (0.39) | EGFRFLT1FLT4KDRSCN9A | |
| SCHEMBL17647916 | 0.89 | RAB9A (0.39) | FLT1FLT4KDRSCN9ASCN5A | |
| SCHEMBL29917313 | 0.89 | RAB9A (0.39) | FLT1FLT4KDRSCN9ASCN5A | |
| SCHEMBL29916838 | 0.89 | SCN9A (0.36) | EGFRFLT1FLT4KDRSCN9A | |
| SCHEMBL17648466 | 0.89 | SCN9A (0.36) | EGFRFLT1FLT4KDRSCN9A | |
| SCHEMBL29916563 | 0.89 | FLT1 (0.35) | EGFRFLT1FLT4KDRSCN9A | |
| SCHEMBL19097554 | 0.89 | FLT1 (0.35) | EGFRFLT1FLT4KDRSCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3798214-B1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2022-09-14 | — | — | EP | claimed |